Skip to content

Clinical trials

Pulmonary Arterial Hypertension trials in the Netherlands

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Pulmonary Arterial Hypertension Country / region: Netherlands Clear all

54 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20031
20042
20062
20071
20084
20092
20103
20114
20121
20133
20141
20152
20163
20174
20181
20193
20201
20216
20222
20233
20242
20252
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed27
Terminated13
Unknown status6
Recruiting4
Active, not recruiting3
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Actelion13
United Therapeutics7
Amsterdam UMC, location VUmc5
Merck Sharp & Dohme LLC4
Novartis Pharmaceuticals4
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA3
Biogen2
GlaxoSmithKline2
University Medical Center Groningen2
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Pulmonary Arterial Hypertension54
Hypertension, Pulmonary16
Hypertension5
Familial Primary Pulmonary Hypertension4
Cardiovascular Diseases2
Connective Tissue Diseases2
Heart Defects, Congenital2
Lung Diseases2
Respiratory Tract Diseases2
Scleroderma, Systemic2

Trials

Showing 1 to 25 of 54. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.